MediBeacon to Present at the Upcoming American Society of Nephrology (ASN) Kidney Week 2025ST. LOUIS, Oct. 30, 2025 (GLOBE NEWSWIRE) -- MediBeacon Inc., a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, today announced that data from the Company’s transdermal GFR technology has been accepted for an oral presentation at the upcoming American Society of Nephrology (ASN) Kidney Week 2025 in Houston, TX, November 5-9, 2025.
MediBeacon receives regulatory approval to sell the Transdermal GFR System in ChinaST. LOUIS, Oct. 21, 2025 (GLOBE NEWSWIRE) -- MediBeacon Inc., a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, announced that MediBeacon’s Lumitrace® (relmapirazin) injection, a non-radioactive, non-iodinated fluorescent GFR agent, has been approved by the National Medical Products Administration (NMPA). Lumitrace will be sold as an integral component of the Transdermal GFR System in China.
